TrialsgrambetaRCTs are beautiful

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy

This guideline cites 3 of the 199 landmark trials in our Cardiology register.

Issued by
ESC
Year
2025
Source
De Backer J, Roos-Hesselink JW, et al. Eur Heart J. 2025;46(43):4462–4568.doi 10.1093/eurheartj/ehaf193

The 2025 ESC guideline treats pregnancy as a cardiovascular stress test that many women fail for the first time, and it builds pre-conception counselling, the modified WHO risk classification and the Pregnancy Heart Team into routine care. Its firmest randomised evidence is in hypertensive disorders — where CHAP finally settled the question of whether to treat mild chronic hypertension — and in pre-eclampsia prophylaxis.

Hypertension in pregnancy2

  • 2022CHAP Core⁠Cardiology · HTN · Hypertension in pregnancyIn 2,408 pregnant women with mild chronic hypertension, antihypertensive treatment targeting a blood pressure below 140/90 mmHg reduced severe pre-eclampsia, medically indicated preterm birth, placental abruption or fetal or neonatal death compared with treatment withheld unless blood pressure reached 160/105 mmHg.RR 0.8295% CI 0.74-0.92Read →
  • 2015CHIPS⁠Cardiology · HTN · Hypertension in pregnancyIn 987 pregnant women with non-proteinuric pre-existing or gestational hypertension, less-tight blood-pressure control did not reduce pregnancy loss or high-level neonatal care compared with tight control targeting a diastolic pressure of 85 mmHg, but led to far more severe maternal hypertension.OR 1.0295% CI 0.77-1.35Read →

Pre-eclampsia: prevention & treatment1

  • 2017ASPRE⁠Cardiology · HTN · Pre-eclampsia preventionIn 1,776 women with singleton pregnancies at high risk of preterm pre-eclampsia on first-trimester screening, aspirin 150 mg daily from 11–14 until 36 weeks reduced delivery with pre-eclampsia before 37 weeks compared with placebo.OR 0.3895% CI 0.20-0.74Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2019ROPAC

    The ESC EORP Registry of Pregnancy and Cardiac Disease — the observational backbone of the risk classification.

  • 1994CLASP

    The first large aspirin trial in pregnancy — neutral at the low dose then used.

  • 2009HYPITAT

    Induction of labour versus expectant monitoring in gestational hypertension.

  • 2022Labetalol vs. nifedipine (2022)

    Head-to-head oral antihypertensives for severe hypertension in pregnancy.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.